A groundbreaking blood test is in development at the University of Cambridge to improve prostate cancer detection accuracy. This test, targeting DNA methylation markers from tumour-released cellular debris, could provide essential insights into cancer presence and severity. Unlike the current PSA test, known for its unreliability and potential for false positives, this new test aims to offer a more precise screening method without the need for invasive biopsies.
Researchers are currently assessing the effectiveness of this innovative test by analyzing samples from over 1,000 men in Europe and Africa. The goal is to identify cancer development in individuals who provided samples decades ago. Clinical trials are planned within the next two years to determine the optimal deployment of this new blood test in the screening process.
Dr. Harveer Dev, leading the research at the Early Cancer Institute, highlighted the promising results of the ongoing development. Dr. Naomi Elster from Prostate Cancer Research emphasized the need for more accurate tools in cancer detection. The new blood test could not only detect cancer but also provide crucial information on its aggressiveness, guiding appropriate treatment decisions.
Men experiencing prostate cancer symptoms like urinary changes or blood in urine can request PSA tests from their GP. As research progresses, this innovative blood test offers hope for more reliable and effective prostate cancer screening in the future.